Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Bachem Aktie 1253020 / CH0012530207

08.10.2025 11:36:51

What is enzymatic ligation and what are the benefits?

Oligonucleotide therapeutics are becoming increasingly complex, pushing traditional manufacturing methods to their limits. As researchers develop longer sequences with sophisticated modifications, a new approach is gaining prominence: enzymatic ligation. This innovative technology is transforming how complex oligonucleotides are produced, offering solutions to longstanding manufacturing challenges. What is enzymatic ligation?Enzymatic ligation is a biocatalytic process that uses specialized enzymes (ligases) to join oligonucleotide fragments together. During traditional chemical synthesis, the desired molecule is built one nucleotide at a time, while in enzymatic ligation, pre-synthesized fragments are assembled into complete sequences.The process relies on ligases, enzymes which cells mainly use to repair DNA breaks. These enzymes recognize the unligated fragment ends and catalyze the formation of phosphodiester bonds, creating seamless connections between fragments.The enzymatic process operates under mild, physiological conditions – moderate temperatures (around 37°C), neutral pH, and aqueous solutions – unlike chemical synthesis, which involves organic solvents and reagents that can affect molecules with delicate chemical modifications. How does enzymatic ligation work?The process typically involves:Fragment synthesis: Short oligonucleotide fragments are synthesized designed with compatible ends (complementary overhangs or blunt ends).Fragment annealing: Hydrogen bonds are formed between the complementary oligo fragments and nicks appear in the double-stranded structure.Bond formation: Ligases catalyze the formation of a stable phosphodiester bond between the 3’-hydroxyl end of one nucleotide with the 5’-phosphate end of the other, effectively sealing the nicks and creating a continuous oligonucleotide chain.Want to learn more about enzymatic ligation and other innovative technologies? This whitepaper explores enzymatic ligation principles, its role in modern oligonucleotide manufacturing, and its benefits for drug development.Download Whitepaper NowThe benefits of enzymatic ligation in drug developmentAlthough understanding enzymatic ligation is important, its real impact becomes clear when compared to traditional manufacturing methods in the production of oligonucleotide APIs.Higher overall yieldsEnzymatic ligation of short oligo fragments yields higher output than full-length synthesis by minimizing coupling steps and avoiding side reactions. Ligases ensure precise alignment, producing cleaner products and simplifying purification.Enhanced scalabilityEnzymatic ligation scales seamlessly from research to commercial production. The consistency stems from the inherent nature of enzymatic catalysis as reactions proceed through well-defined molecular recognition events. Also, the modular nature of fragment assembly enables flexible production strategies, which can be particularly valuable during drug development and clinical investigations.Cost efficiency Enzymatic ligation is a cost-effective method for oligonucleotide manufacturing. It reduces the need for complex purification and costly organic solvents are replaced with aqueous conditions, lowering reagent and waste disposal costs. These efficiencies make it a scalable and commercially attractive option for producing high-purity oligonucleotides. Accommodation of complex modifications Enzymatic ligation enables the incorporation of complex modifications, like lipids, peptides, or PEG, under mild conditions, overcoming limitations of traditional synthesis. This flexibility allows the incorporation of multiple modifications within a single molecule, boosting their stability, targeting, and therapeutic performance. Environmental advantages Operating under aqueous, near-physiological conditions, enzymatic ligation reduces the use of organic solvents and lowers chemical waste. By leveraging high-yield short fragment synthesis and subsequent assembly, it minimizes environmental impact and aligns with sustainability goals in pharmaceutical manufacturing. Enzymatic ligation represents a paradigm shift in oligonucleotide manufacturing. It overcomes limitations of traditional chemical synthesis by harnessing the precision and efficiency of enzymes. With superior yields, simpler processing, environmental benefits, and the ability to incorporate complex modifications, enzymatic ligation is becoming an essential tool in modern oligonucleotide manufacturing. Ready to accelerate your oligonucleotide development? Bachem’s expertise in enzymatic ligation and advanced oligonucleotide manufacturing can help bring your therapeutic concepts from discovery to commercial success. Read more in our whitepaper on Enzymatic Ligation and Other Innovative Technologies: Shaping the Future of Large-scale Oligonucleotide Manufacturing here. Contact our team today to learn how our technologies can support your next breakthrough in gene therapy. Subscribe to our general newsletter/* "function"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn("The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1."),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener("gform_main_scripts_loaded",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener("gform/theme/scripts_loaded",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener("DOMContentLoaded",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook("action",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook("filter",o,r,e,t)},doAction:function(o){gform.doHook("action",o,arguments)},applyFilters:function(o){return gform.doHook("filter",o,arguments)},removeAction:function(o,r){gform.removeHook("action",o,r)},removeFilter:function(o,r,e){gform.removeHook("filter",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+"_"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){"function"!=typeof(t=o.callable)&&(t=window[t]),"action"==r?t.apply(null,e):e[0]=t.apply(null,e)})),"filter"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});/* ]]> */ "*" indicates required fields Δ/* Name* First Last Email Address*Country AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Consent*Privacy Policy I have read, understood and agree to the Privacy Policy.This field is hidden when viewing the formSubmission Time Hours : Minutes /* = 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https://www.bachem.com/wp-content/plugins/gravityforms/images/spinner.svg', true );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "1", currentPage: "current_page", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_1" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_1"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_1" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; gform.core.triggerPostRenderEvents( 1, current_page ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );} ); /* ]]> */The post What is enzymatic ligation and what are the benefits? appeared first on Bachem.Weiter zum vollständigen Artikel bei Bachem Holding AG

Nachrichten zu Bachem AG

  • Relevant
  • Alle
  • vom Unternehmen
  • ?
Keine Nachrichten verfügbar.

Analysen zu Bachem AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Gold auf Allzeithoch, Dollar unter Druck: Kippt jetzt der KI-Hype?

Gold auf Allzeithoch, US-Dollar unter Druck, KI-Hype, US-Schuldenkrise, Stagflation, Zinswende, Government Shutdown, steigende Anleiherenditen, Europa in der Zinsfalle (Frankreich, UK), Japan hebt Leitzinsen an, Immobilien- & Aktienblase in den USA, Notenbanken kaufen Gold.

Im Interview analysiert Marco Ludescher (Dr. Blumer & Partner Vermögensverwaltung Zürich) die Lage an den Kapitalmärkten. Olivia Hähnel (BX Swiss) hakt nach: Was bedeutet die Goldrally für Anleger? Kippt der KI-Hype? Wie wirken Schulden, Inflation und Zinspolitik auf Aktien, Anleihen und Immobilien?

Überblick:
– Gold & Währungen: Rekord-Gold vs. schwacher US-Dollar (DXY).
– Makro & Zinsen: Zinswende der Notenbanken vs. steigende Marktrenditen; Stagflations-Risiko.
– USA-Fokus: Defizite, Shutdown, Konsumdruck, Immobilienmarkt, Tech-Bewertungen.
– Europa: Frankreich & UK unter Druck; Emissionen, Hypotheken, Unternehmenslage.
– Japan: Ende der Ultra-Niedrigzinsen? YCC-Folgen für Yen & Renditen.
– KI & Tech: Investitionswelle (Nvidia, OpenAI, Oracle, CoreWeave, Meta, Amazon) – Chance oder KI-Blase?
– Takeaways: Rolle von Edelmetall-Produzenten, Diversifikation, schrittweises Vorgehen.

👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!

Gold auf Allzeithoch, Dollar unter Druck: Kippt jetzt der KI-Hype?

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’153.37 19.92 B02SIU
Short 13’420.18 13.90 QIUBSU
Short 13’920.37 8.91 U5VSUU
SMI-Kurs: 12’702.08 16.10.2025 17:30:22
Long 12’086.12 18.88 SZPBKU
Long 11’826.74 13.60 S69BTU
Long 11’317.62 8.72 BEFSQU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com